首页> 外文期刊>International Journal of Pharmaceutics >Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer
【24h】

Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer

机译:配体肽接枝的聚乙二醇化脂质体使用HER2靶向肽 - 脂质衍生物用于靶向疾病细胞中的靶向递送:丝氨酸 - 甘氨酸重复肽作为间隔物的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Ligand peptide-grafted PEGylated liposomes have been widely studied for targeted drug delivery systems. Because ligand peptides are commonly grafted using PEG as a spacer on the surface of PEGylated liposomes, the interaction between ligand peptides and their corresponding receptors can be interrupted by steric hindrance of the PEG layer. Therefore, we aimed to develop ligand peptide-lipid derivatives to enhance the targeting efficiency of ligand peptide-grafted PEGylated liposomes, and designed a new ligand peptide-lipid derivatives having serine-glycine repeats (SG)(n) as a spacer based on the peptide length calculated by PyMol (v0.99). We selected KCCYSL (KCC) as the ligand peptide for binding to human epidermal growth factor receptor-2 (HER2). We synthesized new KCC-(SG) n-lipid derivatives (n = 3, 5, 7) and evaluated their cellular association in breast cancer cells. KCC-(SG) n/PEGylated liposomes dramatically increased cellular association on HER2-positive breast cancer cells. The results suggest that KCC can be grafted on the surface of KCC-(SG) n/PEGylated liposomes prepared from KCC-(SG) n-lipid derivatives (n = 3, 5, 7). In summary, we succeeded in developing KCC-(SG) n-lipid derivatives for the preparation of ligand peptide-grafted PEGylated liposomes. (C) 2017 Elsevier B.V. All rights reserved.
机译:配体肽接枝PEG化脂质体已被广泛研究了靶向药物输送系统。因为配体肽使用PEG作为PEG化脂质体的表面上的间隔物通常接枝配体肽及其相应的受体之间的相互作用可以通过PEG层的空间位阻而中断。因此,我们的目的是开发配体的肽 - 脂质衍生物,以提高配体肽接枝的聚乙二醇化的脂质体的靶向效率,并设计了一种新的配体基于所述具有丝氨酸 - 甘氨酸重复(SG)(n)作为间隔物的肽 - 脂质衍生物通过PYMOL(v0.99)来计算肽长度。我们选择KCCYSL(KCC)作为配体的肽结合人表皮生长因子受体2(HER2)。我们合成了新KCC-(SG)N - 脂质衍生物(N = 3,5,7)和评价在乳腺癌细胞中它们的细胞结合。 KCC-(SG)N / PEG化脂质体显着增加在HER2阳性乳腺癌细胞中的细胞相关性。结果表明,KCC可以KCC-(SG)的表面上接枝N /从KCC-(SG)制备PEG化脂质体正脂质衍生物(N = 3,5,7)。总之,我们成功地开发KCC-(SG)N - 脂质衍生物为配体肽接枝PEG化脂质体的制备。 (c)2017年Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号